Q&A: Air Traffic Control for Cancer

David K. Cundiff, MD, Retired internist and palliative care physician from LA County + USC Medical Center; Email: Jeff Shrager, PhD, Director of Research, Cancer Commons; Adjunct Professor, Symbolic Systems Program, Stanford University; Email: Q: After May 17, 2017, you and Jeff Shrager engaged in a robust discussion about the place, if any, […]

Options to Treat a Glioblastoma

Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY; Email: Phone: 888-295-4740 Follow Al Q: You direct an established foundation that supports research and information about brain tumors. What would you do if you yourself were diagnosed with a glioblastoma multiforme (GBM)? A: Now that GBMs are in […]

Lung Cancer Screening…The Clock is Ticking

Paul R Billings MD, PhD, CEO and Chairman of Synergenz LTD Q: Lung cancer screening of smokers (spiral CT over 3 years) is paid for by CMS (reimbursement), has a B endorsement from USPTF (method endorsement), and lots of NEJM papers (academic evidence). As many as 8M eligibles noted since 2012. No more than 400K […]

The Value of Molecular Disease Models for Cancer Treatment Planning

Smruti Vidwans, PhD, Chief Science Officer at CollabRx Q: You have been notified that your article entitled “A Melanoma Molecular Disease Model” is among the top 10% of most cited articles in 10 years at PLOS ONE. Congratulations. What is the essence of that paper, why it is important, and what has changed in the […]

How to Initiate Treatment for Chronic Myelogenous Leukemia March 2016 vs July 2017

Jerald P. Radich, MD, Director of the Molecular Oncology Lab at the Fred Hutchinson Cancer Research Center, and Professor of Medicine at the University of Washington School of Medicine Q: In March 2016, we published your blog about how to initiate therapy for an adult patient newly diagnosed with chronic myeloid leukemia (CML). As of […]

How to Treat Metastatic Colorectal Cancer

Bassel El-Rayes, MD, Professor and Vice Chair for Clinical Research, Department of Hematology and Medical Oncology, Associate Director for Clinical Research, and Director of the Gastrointestinal Oncology Program Winship Cancer Institute of Emory University Q: You have just received a new patient, referred to you from Macon, GA. She is a 52-year-old white woman in […]

You, Me, and 23: DTC Gene Tests

Melinda Roberts, Web and Product Development Lead Globiana Inc. Follow Mindy Q: Many people are interested in their own genes and wonder whether they are predisposed to cancer or other maladies.  You recently participated in the “23 and me” testing process. As a well-educated and informed consumer, did you find that service useful? Were the […]

Leading Retractions in the Cancer Research Literature

Ivan Oransky, MD, and Adam Marcus are co-founders of Retraction Watch. Oransky is Distinguished Writer In Residence at New York University’s Arthur Carter Journalism Institute, and editor at large of MedPage Today. Marcus is managing editor of Gastroenterology & Endoscopy News. Q: You founded “Retraction Watch” in 2010. It has flourished and filled a substantial […]

Is the PBM Now Your Doctor?

Charles Bennett, MD, PhD, MPP, Smart State and Frank P and Jose M Fletcher Chair, Medication Safety and Efficacy, Smart State Center of Economic Excellence, University of South Carolina and the Hollings National Cancer Institute Designated Cancer Center of the Medical University of South Carolina, Charleston, South Carolina William Hrushesky, MD, FACP, Founder and Chief […]

Treating Metastatic Malignant Melanoma, March 2016 vs April 2017

Keith Flaherty, MD, Associate Professor of Medicine, Harvard Medical School; Director of Developmental Therapeutics, Cancer Center, Massachusetts General Hospital Q: A lot has happened in the field of Metastatic Melanoma since March, 2016. In April of 2017, would your reply be any different? If so, in what way, and why? A: The only change from […]